https://www.taxtmi.com/news?id=63298 A bilateral trade arrangement establishes a zero-tariff regime for UK-origin pharmaceuticals, pharmaceutical inputs, and medical technology exported to the United States for at least three years in exchange for UK firms' commitments to increase US investment and job creation; concurrently the UK will raise National Health Service spending on new and effective treatments by roughly 25 percent to facilitate approval and procurement of clinically significant medicines previously excluded on cost-effectiveness grounds. en-us Tue, 02 Dec 2025 02:01:02 +0530 Tue, 02 Dec 2025 02:01:02 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=63298 A bilateral trade arrangement establishes a zero-tariff regime for UK-origin pharmaceuticals, pharmaceutical inputs, and medical technology exported to the United States for at least three years in exchange for UK firms' commitments to increase US investment and job creation; concurrently the UK will raise National Health Service spending on new and effective treatments by roughly 25 percent to facilitate approval and procurement of clinically significant medicines previously excluded on cost-effectiveness grounds. News - Tue, 02 Dec 2025 02:01:02 +0530 https://www.taxtmi.com/news?id=63298